Chronic lymphocytic leukemia (CLL) cells from clinically aggressive cases have a greater capacity to respond to external microenvironmental stimuli, including those transduced through Toll-like-receptor-9 (TLR9). Concomitant microRNA and gene expression profiling in purified CLL cells (n ¼ 17) expressing either unmutated (UM) or mutated (M) IGHV genes selected microRNAs from the miR-17B92 family as significantly upregulated and in part responsible for modifications in the gene expression profile of UM CLL cells stimulated with the TLR9 agonist CpG. Notably, the stable and sustained upregulation of miR-17B92 microRNAs by CpG was preceded by a transient induction of the proto-oncogene MYC. The enforced expression of miR-17, a major member from this family, reduced the expression of the tumor suppressor genes E2F5, TP53INP1, TRIM8 and ZBTB4, and protected cells from serum-free-induced apoptosis (Pp0.05). Consistently, transfection with miR-17B92 family antagomiRs reduced Bromo-deoxy-uridine incorporation in CpG-stimulated UM CLL cells. Finally, miR-17 expression levels, evaluated in 83 CLL samples, were significantly higher in UM (P ¼ 0.03) and ZAP-70 high (P ¼ 0.02) cases. Altogether, these data reveal a role for microRNAs of the miR-17B92 family in regulating pro-survival and growth-promoting responses of CLL cells to TLR9 triggering. Overall, targeting of this pathway may represent a novel therapeutic option for management of aggressive CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course, with an unfavorable prognosis being strongly associated with the expression of unmutated (UM) immunoglobulin heavy variable (IGHV) genes. 1 Such a clinical behavior has been associated with a greater capacity of UM CLL cells to signal through the B-cell receptor (BCR) upon antigen stimulation, suggesting that this feature could contribute to disease progression. In fact, UM BCRs are known to operate as polyreactive receptors that bind to various foreign and self antigens, although often with low affinity. 2, 3 Besides antigen stimulation, the development and progression of CLL could also be affected by other external signals, synergistically cooperating to regulate the proliferation and survival of the malignant clone. In this regard, UM CLL cells have been recently found to respond more efficiently to microenvironmental pro-survival signals than mutated (M) CLL cells, being on the other hand more susceptible to spontaneous apoptosis when these signals are absent. 4 Moreover, UM CLL cells frequently have high levels of the enzyme activation-induced cytidine deaminase and present evidence of ongoing class-switch recombination, both hallmarks of recent activation by microenvironmental signals. 5 Signals that are transmitted through Toll-like-receptor-9 (TLR9) may also have a role in CLL, as they could drive the expansion of CLL cells that express BCRs reactive with DNA or DNA-containing complexes. 6, 7 Notably, CLL cells from patients with aggressive disease, mainly those expressing UM BCRs, respond more effectively to TLR9 stimulation than CLL cells from patients with less aggressive diseases, mainly expressing M IGHV genes, 8, 9 suggesting that the capacity to respond to TLR9 signals could have prognostic relevance in CLL. 9 MicroRNAs represent a class of small non-coding RNAs that act as master regulators of protein expression by inhibiting the translation or inducing the degradation of target messenger RNAs (mRNAs) with partially complementary sites in the 3 0 -untranslated regions. 10 MicroRNAs orchestrate various cellular functions and have been shown to have critical roles in many biological processes, including cell differentiation, apoptosis, proliferation and cancer development by acting either as tumor suppressors or oncogenes. 11 In the case of CLL, several studies have identified certain microRNAs (for example, miR-15a, miR-16-1, miR-21, miR-24, miR-34, miR-155 and let-7 family) as either implicated in CLL pathogenesis or as part of a microRNA signature predicting clinical outcome or drug resistance. 12, 13 However, little is known regarding the capacity of external stimuli to modulate the expression of specific microRNAs and/or microRNA families in CLL. In this regard, studies by our group have recently demonstrated a close correlation between the expression of a particular BCR (that is, IGHV3-23) with relatively higher levels of two key microRNAs (that is, miR-15a and miR-16-1), 14 indicating that the expression of certain microRNAs could be modulated by BCR signals.
In the present study, we provide evidence that TLR9 elicits its response in UM CLL cells through the upregulation, MYC-dependent, of microRNAs from the miR-17B92 family, with the subsequent downregulation of specific miR-17B92 targets. MicroRNAs from the miR-17B92 family are at least in part responsible for the increased proliferation/survival induced by TLR9 triggering in UM CLL cells.
MATERIALS AND METHODS

CLL patients
The study included peripheral blood samples from 117 CLL patients, divided as follows: (i) a discovery panel of 17 CLL utilized for global microRNA profile (miRome) and gene expression profiling (GEP) analyses; (ii) a validation panel of additional 17 CLL cases utilized for transfection/ functional assays; and (iii) a further additional panel of 83 CLL utilized for correlation studies. All patients provided informed consent in accordance with the local Institutional Review Board requirements (IRB-04-2010, Centro di Riferimento Oncologico, Aviano, Italy) and declaration of Helsinki. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation (Amersham Biosciences, Uppsala, Sweden). Detection of IGHV mutational status was performed as previously reported.
14 The 2% cutoff was chosen to discriminate UM versus M CLL cases. Additional biological features of CLL cases entering this study, including expression of ZAP-70 and CD38, interphase fluorescence in-situ hybridization for the main chromosomal abnormalities and the experiments for which each sample has been used are listed in Supplementary Table S1 . 1, 14, 15 In all cases, CLL cells were purified by negative selection using anti-CD3, anti-CD14 and anti-CD16 mouse monoclonal antibodies and Dynabeads coated with a pan anti-mouse IgG antibody (Dynal Biotech, Oslo, Norway). 8 The purity of the CLL cells after negative selection was monitored by flow cytometry, and the percentage of CD5 þ /CD19 þ cells exceeded 98% for all the CLL samples from the patients entering the study.
Cell culture conditions
Freshly isolated negatively selected CLL cells (n ¼ 17) were cultured (1 Â 10 7 cells/ml) in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (Invitrogen, Carlsbad, CA, USA) in the presence or not of 7.5 mg/ml complete phosphorothioate CpG-ODN oligonucleotide 2006 (5-TCGTCGTTTTGTCGTTTTGTCGTT-3; Microsynth, Balgach, Switzerland; hereafter CpG) for 18 h, as previously reported. 8, 9 To amplify the proliferative effect of CpG, selected experiments were carried out in the presence of 100 U/ml interleukin-2 (IL-2; R&D Systems, Minneapolis, MN, USA), as previously reported. 16 In time-course experiments, purified primary CLL cells (n ¼ 3) were stimulated for 3 h with CpG, washed and subsequently resuspended in complete medium to evaluate MYC and miR-17 expression levels at various time points (1 --24 h), as detailed below.
miRome, GEP and data mining tools Total RNA was extracted from purified CLL cells and normal peripheral blood B cells of healthy donors using the TRIZOL Reagent (Invitrogen) and validated for integrity and purity using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Single-color hybridization microarray experiments for miRome were performed with 100-ng total RNA/sample labeled with Cyanine(Cy)-3 dye using the microRNA Complete Labeling System & Hyb Kit (Agilent Technologies). Cy3-labeled RNA was hybridized to the Human microRNA microarray Version 3 from the Sanger database v12.0 (Agilent Technologies).
GEP was performed using the whole-human genome (4 Â 44 K) oligo microarray platform (Agilent Technologies) as previously described. 17 The biological functions of genes were investigated using Onto-Express. 18 Significant Gene Ontology (GO) categories were selected for having a P-value of at least 0.05 and containing at least seven genes per category. To identify the putative microRNAs involved in gene deregulation, GEP data were investigated using the open-source applications 'Targets' Reverse Expression' (T-REX), available at http://aqua.unife.it, and 'Gene Set Enrichment Analysis' (GSEA). 14, 19 Further details are provided in Supplementary Materials and Methods.
Transfection
Three micrograms of microRNA precursor for miR-17 (Ambion, Life Technologies, Carlsbad, CA, USA) or an anti-microRNA mixture comprising anti-microRNAs specific for miR-17, miR-18a, miR-20a and miR-20b (Ambion) were transfected into 7.5 Â 10 6 primary CLL cells with the Amaxa Nucleofector system (Lonza, Basel, Switzerland) according to the manufacturer's guidelines. As negative control, cells were transfected with equal amounts of pre-miR-negative control1 or anti-miR-negative control 1 (Ambion), as applicable.
Quantitative real-time PCR (qRT-PCR)
Expression of selected microRNAs and of the control RNU6B was assessed using a standard TaqMan MicroRNA assay kit (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) according to the manufacture's instructions and as previously described.
14 Briefly, microRNA was reverse transcribed to complementary DNA using gene-specific primers, and the relative amount of each microRNAs was computed using the equation 2
ÀCt where DCt ¼ (Ct microRNA ÀCt RNUB6 ). Expression of specific genes of interest (that is, E2F5, TP53INP1, TRIM8, ZBTB4, MYC, CAD, PGK1, TFAM and b 2 -microglobulin, b 2 M) was evaluated with the TaqMan Gene Expression assay kit (Applied Biosystems); the relative amount of each gene was calculated as above but using the expression of b 2 M as internal control. Fold change between classes was calculated as reported.
14 All qRT-PCR experiments were performed on an Applied Biosystem 7700 Sequence Detection System (Applied Biosystems).
Western blot
Total proteins were extracted from CLL cells (n ¼ 3) collected 18 h after miR-17 transfection, loaded and run in 10% SDS-PAGE gels before transfer to nitrocellulose membranes (GE Healtcare, Little Chalfont, UK) for western analysis and detection by ECL (GE Healtcare) or Immobilon (Millipore Corporation, Billerica, MA, USA). 1:500 rabbit-anti-TP53INP1 (Abcam, Cambridge, MA, USA), 1:1000 rabbit-anti-TRIM8 (Abcam) and 1:1000 rabbitanti-ZBTB4 (Abcam) were used for protein detection. 1:2000 mouse-antia-tubulin antibody (Sigma-Aldrich, St Louis, MO, USA) was used as an internal control. Densitometric quantitation of western blots was determined with the Quantity One 4. RESULTS miRome of CpG-stimulated CLL cells Purified CLL cells were either left unstimulated or stimulated with CpG for 18 h, and analyzed for changes in the microRNA expression profile. Bioinformatics analysis of UM and M CLL samples was performed separately, given their distinct responses to CpG stimulation. 8, 9 Supervised analysis of UM CLL cells yielded a list of 24 differentially expressed microRNAs, of which 21 were upregulated (miR-1260, miR-1274a, miR-1274b, miR-1280, miR-155, miR-155*, miR-17, miR-17*, miR-18a, miR-19b-1*, miR-20a, miR-20b, miR-221, miR-221*, miR-222, miR-29b-1*, miR-30b*, miR-30d*, miR-720, miR-886-3p and miR-92a-1*) and 3 were downregulated (miR-125a-3p, miR-135a* and miR-150*) upon CpG stimulation (Supplementary  Table S2 ). A hierarchical clustering generated using these 24 microRNAs clearly split CpG-stimulated samples from their respective unstimulated counterparts in all the analyzed UM CLL cases ( Figure 1a ).
When the same algorithms for supervised analyses and the same P-value were applied to M CLL, we failed to identify any differences in the miRome by comparing CpG-stimulated and unstimulated M CLL cells. Consistently, in a hierarchical cluster driven by the 24 microRNA differentially expressed in UM CLL, CpG-stimulated M CLL either directly clustered along with unstimulated CLL (4/8 cases; Supplementary Figure S1 ), or displayed changes in microRNA expression only in part resembling those occurring in UM CLL cells (4/8 cases; Supplementary Figure S1 ). However, additional supervised analyses carried out by solely considering the latter cases again failed to identify differentially expressed microRNAs (not shown). These data are overall in keeping with our previous findings that the capability to respond to TLR9 stimulation is frequently reduced in M CLL. 8, 9 GEP of CpG-stimulated CLL cells A parallel GEP comparing CpG-stimulated and unstimulated CLL cells was performed utilizing the same RNAs considered for miRome. Again, bioinformatics analyses were separately performed in UM and M CLL, in agreement with previous results. 8, 9 In the case of UM CLL, 1585 highly differentially expressed genes, 826 upregulated and 759 downregulated upon CpG stimulation, were identified (Supplementary Table S3 ). A hierarchical clustering using these genes correctly separated CLL cells exposed to CpG from those left unstimulated (Figure 1b) . According to bioinformatics tools for global analysis of gene function, among the 50 top-ranked GO categories that were selected as containing differentially expressed genes, 20 (40%) were GO categories related to proliferation and cell cycle control (for example, cell division, DNA replication, mitosis and G1/S transition of cell cycle), apoptosis (for example, regulation of apoptosis, induction of apoptosis and anti-apoptosis) and activation of the NF-kB cascade (Supplementary Table S4 ). 8, 20 When performed on M CLL cells, GEP analysis found a set of 379 differentially expressed genes between CpG-stimulated and unstimulated M CLL cells (Supplementary Figure S2 and Supplementary Table S5 ). Among these genes, only a minority (13 genes) was in common with the genes differentially expressed between CpG-stimulated and unstimulated UM CLL cells (Supplementary  Tables S3 --S5) . More important, bioinformatic analyses revealed CpG stimulation induces changes in mRNA levels of miR-17B92 targets The dramatic changes in miRome and GEP of UM CLL cells upon CpG stimulation prompted us to integrate these data with the aim to identify those microRNAs whose modulated expression could mostly affect gene expression. 19 To do this, the gene expression signature of UM CLL cells was analyzed by taking advantage of the T-REX algorithm, 19 and results were combined with those derived from miRome.
Results of T-REX analysis (complete data available at the website http://aqua.unife.it/Bomben/; password: odraccir) identified 30 microRNAs whose putative mRNA targets were significantly downregulated by TLR9 triggering (Supplementary Figure S3) . Four of these microRNAs, that is, miR-17, miR-20a, miR-20b and miR-1260, were also identified by miRome as upregulated in CpG-stimulated UM CLL cells (Figure 1a and Supplementary Figure S3) . Three of these microRNAs (miR-17, miR-20a and 
, miR-19b-1* and miR-92a-1*) that were also upregulated in miRome of CpG-stimulated UM CLL cells (Figure 1a) , belonged to the miR-17B92 family of microRNA clusters. 21 Data obtained by applying the T-REX algorithm were confirmed by GSEA. By focusing on the gene set grouping the genes sharing the same DNA-binding motifs, including the binding motifs of microRNAs, the gene set containing genes under control of miR-17 presented the lowest nominal P-value (nominal P-value o0.0001, false discovery rate q-value ¼ 0.236). In the context of this gene set, CpG-stimulated UM CLL cells were characterized by a significant enrichment in downregulated genes under control of the miR-17B92 cluster (Supplementary Figure S4) .
Collectively, both miRome and in-silico analyses of GEP data revealed that CpG stimulation upregulated expression of microRNAs from the miR-17B92 family and downregulated their putative mRNA targets in UM CLL. To further validate these findings, the expression levels of four microRNAs from the miR-17B92 family, that is, miR-17, miR-18a, miR-20a and miR-20b, were quantified by real-time RT-PCR. As shown in Figure 2a , all four microRNAs were expressed at significantly higher levels in CpGstimulated UM CLL cells than in their unstimulated counterparts. Moreover, given the notion that members of the same microRNA cluster are transcribed as a single pri-microRNA and frequently exhibit similar expression patterns, 22 miR-17, miR-18a and miR-20a followed a similar expression profile across the different CLL samples (Figure 2b) . Finally, for all these microRNAs, results of qRT-PCR experiments and miRome were strongly correlated (Po0.001) (Supplementary Figure S5a) .
Effects of miR-17B92 microRNAs on expression of candidate target genes
According to the T-REX analysis, 57 out of the 759 genes that were downregulated in CpG-stimulated UM CLL cells (7.5%) were putative mRNA targets of the miR-17B92 family (Supplementary  Table S7 ). Of these genes, we selected TP53INP1, E2F5, ZBTB4 and TRIM8 for further studies, given their potential activity as tumor suppressors and their roles in regulating cell cycle and apoptosis. 23 --26 As shown in Figure 2c , qRT-PCR experiments confirmed the downregulation of these genes upon CpG stimulation, consistent with GEP results (Supplementary Figure S5b) .
Expression of TP53INP1, E2F5, ZBTB4 and TRIM8 was also significantly downregulated in primary CLL cells transiently transfected with miR-17 (mean fold change of miR-17 levels after 18 h ¼ 477.57±202.57), both at mRNA (Figure 3a) and protein (Figures 3b and c ) levels, suggesting a regulation of their expression by miR-17B92 family members, as reported previously in other cell systems. Table S3 ) and qRT-PCR experiments (Figure 4a) . Moreover, transcripts for three established MYC target genes (that is, CAD, PGK1 and TFAM), selected for being functionally related to cell metabolism functions but unconnected to known biological activities in lymphoproliferative disorders, 35 resulted in upregulation of CpG-stimulated UM CLL in comparison with their respective unstimulated counterparts both in GEP (Po0.001 in all cases; data not shown) and in qRT-PCR experiments (Figure 4a) . Conversely, in the context of M CLL, neither MYC nor the three MYC targets were found among the differentially expressed genes characterizing CpG-stimulated cells (Supplementary Table S5 ).
In keeping with these data, time-course experiments showed that CpG stimulation of primary UM CLL cells resulted in transient induction of MYC, peaking at 3 h from the end of CpG exposure, followed by a slower but sustained induction of miR-17 levels that reached a peak at 6 h, and were maintained at least until 24 h from the removal of CpG from the culture media (Figure 4b) . A similar kinetic profile was observed when expression levels of other members of the miR-17B92 family (that is, miR18a and miR20a) were investigated (not shown). These findings, along with the known activity of MYC as a master regulator of miR-17B92 cluster in other cell systems, 35 --39 strongly suggest an associative interaction between MYC and miR-17B92 also in CLL.
MicroRNAs from the miR-17B92 family regulate apoptosis and proliferation in primary UM CLL cells Negatively purified UM CLL cells were transfected either with pri-miR-17 or scrambled control, and evaluated for apoptosis and Figure 3 . Effect of miR-17 overexpression on mRNA and protein levels of selected genes. (a) miR-17 overexpression and mRNA levels. Effects of miR-17 overexpression on mRNA levels of E2F5, TP53INP1, TRIM8 and ZBTB4 in six primary CLL samples. Gene expression levels were measured by qRT-PCR using TaqMan Gene Expression Assays (Applied Biosystems) at 18 h after transfection. (b) miR-17 overexpression and protein levels---upper panel. Relative TP53INP1, TRIM8 and ZBTB4 protein expression levels of three primary CLL cases transfected with a scrambled control versus a precursor for miR-17, assessed by western blot. Control refers to protein levels in untreated condition. a-Tubulin levels were used as loading control in all cases. Lower panel: effects of miR-17 overexpression on protein levels of E2F5, TP53INP1, TRIM8 and ZBTB4 in three primary CLL samples. Protein expression levels were measured by western blot experiment at 18 h after transfection. In all graphs, values are represented as mean fold expression with respect to transfection of the same CLL cells with scrambled control. Asterisk indicate P-value o0.05 (Student's t-test). A dashed line indicates the reference level of gene expression (1.0). nd, not done.
miR-17B92 regulates proliferation in CLL R Bomben et al viability after 24 --96 h of culture in serum-deprived culture medium. qRT-PCR analysis of miR-17 levels showed that transfection was successful in all cases, with an increase in miR-17 expression levels ranging from 24-to 800-fold compared with cells transfected with scrambled control (Po0.0034; Figure 5a ). Both miR-17-and scrambled control-transfected UM CLL cells underwent apoptosis throughout the culture period. However, miR-17-transfected UM CLL cells always showed a slightly greater viability, compared with cells transfected with scrambled control. These differences in the percentage of viable cells were already evident at 24 h (P ¼ 0.021) and peaked at 48 h (P ¼ 0.010) of culture (Figure 5b) . In complementary experiments, purified UM CLL cells were transfected with a mixture of antagomiRs against miR-17, miR-18a, miR-20a and miR-20b or an anti-miR-negative control (Figure 5c ). In samples transfected with the negative control, CpG stimulation increased the levels of miR-17B92 microRNAs and induced leukemic cell proliferation, as evidenced by BrdU incorporation. The antagomiR mixture inhibited the CpG-induced rise in microRNA levels and concomitantly reduced the percentage of BrdU-positive cells (Figure 5d and Supplementary Figure S7) .
Association between miR-17, IGHV mutational status and ZAP-70
The expression level of miR-17 was analyzed by qRT-PCR in a series of 83 CLL cases for which information regarding different biological parameters was available (Supplementary Table S1 ). As shown in Figure 6 , the levels of miR-17 were significantly higher in UM CLL and in ZAP-70-positive samples compared with their relative counterparts (P ¼ 0.0324 and P ¼ 0.0264, respectively). This difference was even more evident when CLL cells expressing UM IGHV genes and high ZAP-70 levels were compared with cells with M IGHV genes and low/absent ZAP-70 (P ¼ 0.0156; Figure 6 ). Finally, no significant correlation was found between miR-17 and MYC baseline levels in the same CLL series (Supplementary Figure  S8) , and MYC was not differentially expressed between the different prognostic groups (data not shown).
DISCUSSION
The capability of the malignant cells to respond to microenvironmental stimuli has recently emerged as an important determinant of the clinical course in CLL. In particular, CLL cells from patients with aggressive disease typically respond with increased survival CLL cells from patients with indolent disease usually do not respond or may even respond by undergoing apoptosis. 4, 8, 43 In the case of TLR9 signaling, these distinct cellular responses have been associated with differences in intracellular signal transduction. 8, 9, 20, 43 In particular, CpG-stimulated UM CLL cells exhibit greater and prolonged activation of several important downstream signaling molecules, including the transcription factor NF-kB and the kinases Akt, ERK and JNK. Prolonged activation of these downstream signaling molecules has been associated with a greater capacity to traverse the G1/S checkpoint of the cell cycle, as evidenced by [3H]thymidine or BrdU incorporation. In contrast, CpG-stimulated M CLL cells show only transient activation of these downstream signaling pathways, usually insufficient for a complete S-phase progression. 8 Here, we show that differences in the response to TLR9 signaling between UM and M CLL were also demonstrated at GEP and miRome levels. Of the more than 1500 genes that changed expression following CpG stimulation of UM CLL cells and the B400 genes representing the differential gene expression signature of CpG-stimulated M CLL cells, only a tiny minority (13 genes in our experiments) were shared. More important, the genes that changed expression in UM and M CLL cells belonged to different GO categories, in accordance with the distinct cellular responses induced by TLR9 triggering in these two prognostic subsets. 8, 9 Moreover, a clear-cut miRome signature comprising the differential expression of 24 microRNAs, 21 upregulated, was found to characterize CpG-stimulated UM CLL cells. Conversely, no differences in miRome were obtained by comparing Figure S1) . With the aim to identify the microRNAs whose modulated expression was primarily responsible for GEP changes, ad-hoc bioinformatics algorithms were applied to integrate miRome and GEP data. 19 This approach allowed the identification of microRNAs belonging to the miR-17B92 family as important regulators of the gene expression profile induced by CpG stimulation in UM CLL cells.
The miR-17B92 family is composed of 15 microRNAs organized in three clusters. The prototypic cluster is the miR-17B92 polycistronic element (a.k.a. Oncomir-1), 38, 44 located at 13q31.3 and composed of six microRNAs (miR-17, miR-18a, miR-19a, miR20a, miR-19b-1 and miR-92a-1), whose transcription is directly transactivated by c-myc. 38, 44 The two other miR-17B92 clusters are located on chromosome X and chromosome 7. 21 Notably, a member of one of these paralog clusters, that is, mir20b, was also upregulated by CpG stimulation, further emphasizing the involvement of this family in the cascade of events triggered by TLR9 engagement of UM CLL cells. The association of miR-17B92 with a broad range of cancers underlines the clinical significance of this locus, and suggests its role in many fundamental pathobiological processes, including tumorigenesis. 38,45 --47 In the present study, as many as 7.5% of the downregulated genes in CpG-stimulated UM CLL cells turned out to be in-silico miR-17B92 targets. These downregulated genes included ZBTB4 and TP53INP1, which regulate apoptosis through CDKN1A and TP53;
25,26 E2F5, necessary for G1 arrest; 24 and TRIM8, which is involved in the degradation of SOCS1, a well-known regulator of the response to CpG. 23, 48 All these genes were identified as direct targets of miR-17, as evidenced by their significant downregulation upon ectopic miR-17 overexpression. In agreement with these results, miR-17 transfection was also demonstrated to be sufficient to reduce apoptosis induced by serum deprivation in a series of primary UM CLL cells.
The miR-17B92 locus has also been shown to regulate cell cycle progression by selectively targeting a set of genes involved in the G1/S-phase transition. 38, 44, 49, 50 In this context, ectopic expression of miR-17 alone was reported to increase the proliferation rate of HEK293 T cells, by suppressing the G1/S-phase checkpoint of the cell cycle. 38, 44 Thus, lack of miR-17B92 upregulation may in part explain the inability of M CLL cells to traverse the G1/S checkpoint following CpG stimulation. In line with this possibility, we show that transfection of primary CLL cells with a mixture of antagomiRs targeting selected miR-17B92 microRNAs inhibited CpG-induced BrdU incorporation, a marker of DNA synthesis and S-phase progression.
The presence of an UM IGHV gene configuration and elevated ZAP-70 levels are both strongly associated with unfavorable prognosis in CLL. 1 Here, we report that expression of miR-17, the prototypic member of the miR-17B92 family, is significantly higher in UM CLL cells expressing high ZAP-70 compared with M CLL cells with a ZAP70 low phenotype. Interestingly, other microRNAs that we found to be upregulated in UM CLL cells upon CpG stimulation, such as miR-155, miR-221 and miR-222, have been also associated with established prognostic factors or with shorter survival in CLL. 12 Overall, the higher expression of microRNAs that are induced by TLR9 triggering in UM/ZAP70 high CLL cells could suggest that these cells are more frequently subjected to signals capable of activating the TLR9 pathway. Alternatively, UM/ZAP70 high cells may have a greater capacity to respond to microenvironmental signals, including those delivered through TLR9, as previously elaborated. 51 --54 The GEP analysis performed in this study also showed that MYC was substantially upregulated in UM CLL cells upon CpG stimulation, but not in M CLL cells. Consistently, the transcriptional activity of MYC, defined by the expression of three independent target genes (CAD, TFAM and PGK1), increased in CpG-stimulated UM CLL cells. Pathological activation of MYC, which is one of the most common oncogenic events in human cancer, has been shown to result in extensive reprogramming of microRNA expression by tumor cells. 55 In this regard, although MYC predominantly induces downregulation of microRNA expression, the miR-17B92 cluster is known to be directly upregulated by MYC. 35 --37,44 Results from the present study provide evidence of an associative interaction between MYC and miR-17B92 family also in CLL cells. Despite this, we failed to find a correlation between miR-17 and MYC baseline levels in a relatively wide CLL series (Supplementary Figure S8) . This lack of correlation could be explained by considering the different kinetics of MYC and miR-17 modulation upon in vitro CpG cell stimulation, as demonstrated here in CLL (Figure 4b) , and in other cellular models. 35 --37 Alternatively, a MYC-independent pathway leading to increased miR-17 expression has to be also considered.
Induction of microRNAs from the miR-17B92 family can in turn regulate B-cell proliferation and survival by downregulating a series of genes with anti-proliferative and/or pro-apoptotic activities. A comprehensive scheme of the cascade of events triggered by CpG engagement of TLR9 in UM CLL cells is drawn in Figure 7 .
What still remains to be established is the mechanism(s) through which TLR9 signaling leads to enhanced upregulation of MYC. In this regard, we can only speculate that an overexpression of MYC following TLR9 stimulation may occur by way of the MyD88-ERK pathway, as demonstrated in murine models. 6, 56 The recent identification of an activating mutation involving the MyD88 gene in a fraction of CLL with an aggressive clinical behavior 57 suggests to investigate in these cases the constitutive MYC/miR-17 levels or the capability of MyD88 mutated cells to modulate their expression upon CpG stimulation in vitro.
In summary, data from the present report suggest that the TLR9 pathway, through the activity of specific microRNAs, could be an important link between the microenvironment and the miR-17B92 regulates proliferation in CLL R Bomben et al intracellular machinery that regulates CLL cell proliferation and survival. Further support for this possibility comes from the notion that the CLL BCRs, particularly those bearing UM IGHV domains, frequently recognize autoantigens that are either directly associated with DNA or are colocalized in apoptotic blebs with DNA-containing protein complexes. 58, 59 The reactivity of the leukemic BCRs could allow efficient delivery of exogenous DNA to endosomes, where TLR9 is located and activated. In line with this possibility, recent GEP analysis showed that CLL cells located in lymph nodes overexpress TLR target genes, indicating that this pathway is frequently activated in vivo. 60 Together, these data suggest that the TLR9 pathway may have a role in the pathogenesis of aggressive CLL and, as such, could represent a novel target for therapeutic intervention.
